The rise and fall of dimebon

Research output: Contribution to journalArticle

69 Citations (Scopus)

Abstract

Dimebon (latrepirdine) was developed and used in Russia as an over-thecounter oral antihistamine for allergy treatment. In the early 1990s, Dimebon was characterized as a low-affinity NMDA receptor antagonist by Dr. Sergey Bachurin and his colleagues. An initial small-scale, open-label trial of Dimebon in 14 Alzheimer's disease (AD) patients demonstrated potential efficacy. Dimebon was then patented for the treatment of neurodegenerative disorders and licensed by Medivation. Extremely promising results were obtained in a double-blind, placebocontrolled, phase II AD trial in 183 patients; however, a phase II trial of Dimebon in 91 Huntington's disease patients was much less successful. Recently, a phase III AD trial of Dimebon in 598 patients failed to result in any significant improvement in primary or secondary outcomes. The failure of Dimebon may be in large part due to insufficient understanding of its mechanism of action. The NMDA receptor blocking activity of Dimebon is too weak to be physiologically relevant, while the proposed "novel mitochondrial mechanism of action" lacks credible scientific evidence or a molecular target. Independent studies indicate that the clinical effects of Dimebon most likely result from inhibition of histamine H1 and serotonin 5-HT 6 receptors. Careful preclinical studies of novel potential therapies are needed to minimize chances of making similar costly mistakes in the future.

Original languageEnglish (US)
Pages (from-to)518-523
Number of pages6
JournalDrug News and Perspectives
Volume23
Issue number8
DOIs
StatePublished - Oct 2010

Fingerprint

N-Methyl-D-Aspartate Receptors
Alzheimer Disease
latrepirdine
Histamine Antagonists
Russia
Huntington Disease
Neurodegenerative Diseases
Histamine
Serotonin
Hypersensitivity
Therapeutics
Alzheimer Disease 14
Clinical Studies
serotonin 6 receptor
Inhibition (Psychology)

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery

Cite this

The rise and fall of dimebon. / Bezprozvanny, Ilya.

In: Drug News and Perspectives, Vol. 23, No. 8, 10.2010, p. 518-523.

Research output: Contribution to journalArticle

@article{d1c51d1d7b2646a28fc926c7da8268a5,
title = "The rise and fall of dimebon",
abstract = "Dimebon (latrepirdine) was developed and used in Russia as an over-thecounter oral antihistamine for allergy treatment. In the early 1990s, Dimebon was characterized as a low-affinity NMDA receptor antagonist by Dr. Sergey Bachurin and his colleagues. An initial small-scale, open-label trial of Dimebon in 14 Alzheimer's disease (AD) patients demonstrated potential efficacy. Dimebon was then patented for the treatment of neurodegenerative disorders and licensed by Medivation. Extremely promising results were obtained in a double-blind, placebocontrolled, phase II AD trial in 183 patients; however, a phase II trial of Dimebon in 91 Huntington's disease patients was much less successful. Recently, a phase III AD trial of Dimebon in 598 patients failed to result in any significant improvement in primary or secondary outcomes. The failure of Dimebon may be in large part due to insufficient understanding of its mechanism of action. The NMDA receptor blocking activity of Dimebon is too weak to be physiologically relevant, while the proposed {"}novel mitochondrial mechanism of action{"} lacks credible scientific evidence or a molecular target. Independent studies indicate that the clinical effects of Dimebon most likely result from inhibition of histamine H1 and serotonin 5-HT 6 receptors. Careful preclinical studies of novel potential therapies are needed to minimize chances of making similar costly mistakes in the future.",
author = "Ilya Bezprozvanny",
year = "2010",
month = "10",
doi = "10.1358/dnp.2010.23.8.1500435",
language = "English (US)",
volume = "23",
pages = "518--523",
journal = "Drug News and Perspectives",
issn = "0214-0934",
publisher = "Prous Science",
number = "8",

}

TY - JOUR

T1 - The rise and fall of dimebon

AU - Bezprozvanny, Ilya

PY - 2010/10

Y1 - 2010/10

N2 - Dimebon (latrepirdine) was developed and used in Russia as an over-thecounter oral antihistamine for allergy treatment. In the early 1990s, Dimebon was characterized as a low-affinity NMDA receptor antagonist by Dr. Sergey Bachurin and his colleagues. An initial small-scale, open-label trial of Dimebon in 14 Alzheimer's disease (AD) patients demonstrated potential efficacy. Dimebon was then patented for the treatment of neurodegenerative disorders and licensed by Medivation. Extremely promising results were obtained in a double-blind, placebocontrolled, phase II AD trial in 183 patients; however, a phase II trial of Dimebon in 91 Huntington's disease patients was much less successful. Recently, a phase III AD trial of Dimebon in 598 patients failed to result in any significant improvement in primary or secondary outcomes. The failure of Dimebon may be in large part due to insufficient understanding of its mechanism of action. The NMDA receptor blocking activity of Dimebon is too weak to be physiologically relevant, while the proposed "novel mitochondrial mechanism of action" lacks credible scientific evidence or a molecular target. Independent studies indicate that the clinical effects of Dimebon most likely result from inhibition of histamine H1 and serotonin 5-HT 6 receptors. Careful preclinical studies of novel potential therapies are needed to minimize chances of making similar costly mistakes in the future.

AB - Dimebon (latrepirdine) was developed and used in Russia as an over-thecounter oral antihistamine for allergy treatment. In the early 1990s, Dimebon was characterized as a low-affinity NMDA receptor antagonist by Dr. Sergey Bachurin and his colleagues. An initial small-scale, open-label trial of Dimebon in 14 Alzheimer's disease (AD) patients demonstrated potential efficacy. Dimebon was then patented for the treatment of neurodegenerative disorders and licensed by Medivation. Extremely promising results were obtained in a double-blind, placebocontrolled, phase II AD trial in 183 patients; however, a phase II trial of Dimebon in 91 Huntington's disease patients was much less successful. Recently, a phase III AD trial of Dimebon in 598 patients failed to result in any significant improvement in primary or secondary outcomes. The failure of Dimebon may be in large part due to insufficient understanding of its mechanism of action. The NMDA receptor blocking activity of Dimebon is too weak to be physiologically relevant, while the proposed "novel mitochondrial mechanism of action" lacks credible scientific evidence or a molecular target. Independent studies indicate that the clinical effects of Dimebon most likely result from inhibition of histamine H1 and serotonin 5-HT 6 receptors. Careful preclinical studies of novel potential therapies are needed to minimize chances of making similar costly mistakes in the future.

UR - http://www.scopus.com/inward/record.url?scp=77957138323&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77957138323&partnerID=8YFLogxK

U2 - 10.1358/dnp.2010.23.8.1500435

DO - 10.1358/dnp.2010.23.8.1500435

M3 - Article

C2 - 21031168

AN - SCOPUS:77957138323

VL - 23

SP - 518

EP - 523

JO - Drug News and Perspectives

JF - Drug News and Perspectives

SN - 0214-0934

IS - 8

ER -